HIV PrEP Econ Search Strategies Revised 2016 Apr 19 OVID

Size: px
Start display at page:

Download "HIV PrEP Econ Search Strategies Revised 2016 Apr 19 OVID"

Transcription

1 HIV PrEP Econ Search Strategies Revised 2016 Apr 19 OVID Database: Embase Classic+Embase <1947 to 2016 April 19>, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) <1946 to Present> Search Strategy: HIV Seronegativity/ (50628) 2 ((AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*) adj2 (negativ* or seronegativ* or sero-negativ*)).tw,kw. (2236) 3 ((HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II) adj2 (negativ* or seronegativ* or sero-negativ*)).tw,kw. (30048) 4 ((uninfected or "not infected") adj2 (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (6885) 5 ((uninfected or "not infected") adj2 (AIDs or (acquired immune deficiency* adj2 virus) or (acquired virus*)).tw,kw. (314) 6 (without adj (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (3368) 7 (without adj (AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*)).tw,kw. (2070) 8 ((non or "not") adj (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II) adj positiv*).tw,kw. (187) 9 (non-positiv* adj (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (0) 10 ((non or "not") adj (AIDs or (acquired immune deficiency* adj2 virus) or (acquired virus*) adj positiv*).tw,kw. (2) 11 (non-positiv* adj (AIDs or (acquired immune deficiency* adj2 virus) or (acquired virus*)).tw,kw. (0) 12 or/1-11 (88933) 13 exp HIV Infections/pc [Prevention & Control] (85035) 14 (prevent* adj3 (AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*)).tw,kw. (10332) 15 (prevent* adj3 (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (37399) 16 (prophyla* adj3 (AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*)).tw,kw. (695) 17 (prophyla* adj3 (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (3516) 18 or/13-17 (107323) 19 Anti-Retroviral Agents/ (39845) 20 Anti-HIV Agents/ (44938)

2 21 (antiretrovir* or anti-retrovir* or antihiv* or anti-hiv* or antiaids or anti-aids).tw,kw. (134258) 22 Adenine/aa (7935) 23 tenofovir*.tw,kw. (11225) rn. (0) 25 (rilpivirine or edurant or TMC-278 or TMC278 or UNII-FI96A8X663).tw,kw. (1169) 26 rilpivirine.rn. (1190) 27 (dapivirine or TMC-120 or TMC120 or UNII-TCN4MG2VXS).tw,kw. (393) 28 dapivirine.rn. (38) 29 Truvada.tw,kw. (1301) 30 ("TDF-FTC" or "FTC-TDF" or "TDF/FTC" or "FTC/TDF").tw,kw. (1232) rn. (0) 32 or/19-31 (181872) 33 Primary Prevention/ or Pre-Exposure Prophylaxis/ (48334) and 33 (995) and (18 or 34) (5952) and 32 (19266) 37 exp HIV Infections/ (567911) 38 exp HIV/ (243845) 39 HIV Seroprevalence/ (11170) 40 (AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*).tw,kw. (416114) 41 (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II).tw,kw. (587791) 42 or/37-41 (874497) 43 Pre-Exposure Prophylaxis/ (1031) 44 ((pre-expos* or preexpos*) adj3 prophyla*).tw,kw. (2895) 45 ((pre-expos* or preexpos*) adj3 protect*).tw,kw. (153) 46 PrEP.tw,kw. (6956) 47 or/43-46 (8742) 48 (1 or 42) and 47 (2948) or 36 or 48 (24683) 50 Economics/ (249710) 51 exp "Costs and Cost Analysis"/ (483179) 52 Economics, Nursing/ (37284) 53 Economics, Medical/ (43339) 54 Economics, Pharmaceutical/ (8885) 55 exp Economics, Hospital/ (712078) 56 Economics, Dental/ (37313) 57 exp "Fees and Charges"/ (64719) 58 exp Budgets/ (35494) 59 budget*.ti,ab. (50445) 60 (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ti. (333036) 61 (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ab. /freq=2 (474484)

3 62 (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab. (259087) 63 (value adj2 (money or monetary)).ti,ab. (3840) 64 exp models, economic/ (134649) 65 Quality-Adjusted Life Years/ (21871) 66 (life qualities or life quality or quality adjusted or adjusted life or qol or qoly or qolys or hrqol or qaly or qalys or qale or qales).tw. (129253) 67 exp Models, Economic/ (134649) 68 economic model*.ti,ab. (5411) 69 agent-based.ti,ab. (4313) 70 individual-based.ti,ab. (4566) 71 transmission dynamic?.ti,ab. (4378) 72 deterministic.ti,ab. (20638) 73 compartmental.ti,ab. (18520) 74 (compartment* adj2 model*).ti,ab. (34626) 75 (discrete event? adj2 (model* or simulat*)).ti,ab. (1343) 76 ordinary differential equation?.ti,ab. (4141) 77 ode model*.ti,ab. (420) 78 Stochastic Processes/ (312971) 79 stochastic.ti,ab. (53669) 80 markov chains/ (71457) 81 markov.ti,ab. (33172) 82 monte carlo method/ (49230) 83 monte carlo.ti,ab. (66944) 84 exp Decision Theory/ (11878) 85 (decision* adj2 (tree* or analy* or model*)).ti,ab. (36217) 86 or/50-85 ( ) and 86 (3559) 88 "Quality of Life"/ (449525) 89 quality-adjusted life years/ (21871) 90 (life adj1 (quality or qualities)).ti,ab. (13547) 91 (adjusted adj1 (quality or life)).ti,ab. (25248) 92 (qol or qoly or qolys or hrqol or qaly or qalys or qale or qales).ti,ab. (107694) 93 or/88-92 (495602) and 93 (485) or 94 (3714) 96 exp Animals/ not (exp Animals/ and Humans/) ( ) not 96 (2692) use prmz (1000) 99 ((AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*) adj2 (negativ* or seronegativ* or sero-negativ*)).tw,kw. (2236) 100 ((HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV- 2 or LAV-II) adj2 (negativ* or seronegativ* or sero-negativ*)).tw,kw. (30048) 101 ((uninfected or "not infected") adj2 (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV- 2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (6885)

4 102 ((uninfected or "not infected") adj2 (AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immunodeficiency virus*)).tw,kw. (314) 103 (without adj (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (3368) 104 (without adj (AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*)).tw,kw. (2070) 105 ((non or "not") adj (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II) adj positiv*).tw,kw. (187) 106 (non-positiv* adj (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (0) 107 ((non or "not") adj (AIDs or (acquired immune deficiency* adj2 virus) or (acquired virus*) adj positiv*).tw,kw. (2) 108 (non-positiv* adj (AIDs or (acquired immune deficiency* adj2 virus) or (acquired virus*)).tw,kw. (0) 109 or/ (41776) 110 exp Human immunodeficiency virus infection/pc [Prevention] (41728) 111 (prevent* adj3 (AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*)).tw,kw. (10332) 112 (prevent* adj3 (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (37399) 113 (prophyla* adj3 (AIDs or (acquired immune deficiency* adj2 virus) or (acquired virus*)).tw,kw. (695) 114 (prophyla* adj3 (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II)).tw,kw. (3516) 115 or/ (76065) 116 antiretrovirus agent/ (36296) 117 anti human immunodeficiency virus agent/ (16012) 118 (antiretrovir* or anti-retrovir* or antihiv* or anti-hiv* or antiaids or anti-aids).tw,kw. (134258) 119 tenofovir/ (15286) 120 tenofovir.rn. (13081) 121 rilpivirine/ (1389) 122 rilpivirine.rn. (1190) 123 dapivirine/ (407) 124 dapivirine.rn. (38) 125 emtricitabine plus tenofovir disoproxil/ (2575) 126 Truvada.tw,kw. (1301) 127 ("TDF-FTC" or "FTC-TDF" or "TDF/FTC" or "FTC/TDF").tw,kw. (1232) rn. (0) 129 or/ (165707) 130 prophylaxis/ or pre-exposure prophylaxis/ (92834) and 130 (2323) and (115 or 131) (3824) and 129 (14491) 134 exp Human immunodeficiency virus infection/ (323336)

5 135 exp Human immunodeficiency virus/ (243845) 136 human immunodeficiency virus prevalence/ (8079) 137 (AIDs or (acquired immune deficiency* adj2 virus) or (acquired immunodeficiency* adj2 virus*) or human immunodeficiency virus* or human immuno-deficiency virus*).tw,kw. (416114) 138 (HIV or HIV-1 or HIV1 or HIV-I or HIVI or HIV-2 or HIV2 or HIV-2 or HIV-II or HIVII or HTLV* or LAV-2 or LAV-II).tw,kw. (587791) 139 or/ (843839) 140 pre-exposure prophylaxis/ (1031) 141 ((pre-expos* or preexpos*) adj3 prophyla*).tw,kw. (2895) 142 ((pre-expos* or preexpos*) adj3 protect*).tw,kw. (153) 143 PrEP.tw,kw. (6956) 144 or/ (8742) and 144 (2865) or 133 or 145 (18353) 147 economics/ (249710) 148 exp cost/ (483179) 149 exp health economics/ (690785) 150 exp fee/ (64719) 151 budget/ (33113) 152 budget*.ti,ab. (50445) 153 (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ti. (333036) 154 (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or finance or finances or financed).ab. /freq=2 (474484) 155 (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab. (259087) 156 (value adj2 (money or monetary)).ti,ab. (3840) 157 statistical model/ (198616) 158 economic model*.ti,ab. (5411) 159 probability/ (115768) 160 mathematical model/ (215080) 161 agent-based.ti,ab. (4313) 162 individual-based.ti,ab. (4566) 163 transmission dynamic?.ti,ab. (4378) 164 deterministic.ti,ab. (20638) 165 compartment model/ (12040) 166 compartmental.ti,ab. (18520) 167 (compartment* adj2 model*).ti,ab. (34626) 168 (discrete event? adj2 (model* or simulat*)).ti,ab. (1343) 169 ordinary differential equation?.ti,ab. (4141) 170 ode model*.ti,ab. (420) 171 stochastic model/ (8625) 172 stochastic.ti,ab. (53669) 173 markov.ti,ab. (33172) 174 monte carlo method/ (49230) 175 monte carlo.ti,ab. (66944)

6 176 decision theory/ (2468) 177 (decision* adj2 (tree* or analy* or model*)).ti,ab. (36217) 178 or/ ( ) and 178 (2917) 180 exp "quality of life"/ (470578) 181 (life adj1 (quality or qualities)).ti,ab. (13547) 182 (adjusted adj1 (quality or life)).ti,ab. (25248) 183 (qol or qoly or qolys or hrqol or qaly or qalys or qale or qales).ti,ab. (107694) 184 or/ (501752) and 184 (419) or 185 (3073) 187 exp animal experimentation/ or exp models animal/ or exp animal experiment/ or nonhuman/ or exp vertebrate/ ( ) 188 exp human/ or exp human experimentation/ or exp human experiment/ ( ) not 188 ( ) not 189 (3058) 191 conference abstract.pt. ( ) not 191 (2899) use emczd (2337) or 193 (3337) 195 remove duplicates from 194 (2727) [TOTAL UNIQUE RECORDS] use prmz (969) [MEDLINE UNIQUE RECORDS] use emczd (1758) [EMBASE UNIQUE RECORDS] *************************** Cochrane Library Search Name: HIV Pre-Exposure Prophylaxis (PrEP) Date Run: 19/04/16 21:02: Description: OHRI (Kednapa) Dec 1 (re-run 2016 Apr 6) ID Search Hits #1 [mh "HIV Seropositivity"] Publication Year from 1988 to #2 [mh "HIV Seronegativity"] 157 #3 ((AIDS or ("acquired immune deficiency" near/2 virus*) or ("acquired immunodeficiency" near/2 virus*) or ("human immunodeficiency" next virus*) or ("human immuno-deficiency" next virus*)) near/2 (negativ* or seronegativ* or sero-negativ*)):ti,ab,kw 68 #4 ((HIV or "HIV-1" or HIV1 or "HIV-I" or HIVI or "HIV-2" or HIV2 or "HIV-2" or "HIV-II" or HIVII or HTLV* or "LAV-2" or "LAV-II") near/2 (negativ* or seronegativ* or (sero next negativ*))):ti,ab,kw 864 #5 ((uninfected or "not infected") near/2 (HIV or "HIV-1" or HIV1 or "HIV-I" or HIVI or "HIV-2" or HIV2 or "HIV-2" or "HIV-II" or HIVII or HTLV* or "LAV-2" or "LAV-II")):ti,ab,kw 409 #6 ((uninfected or "not infected") near/2 (AIDS or ("acquired immune deficiency" near/2 virus*) or ("acquired immunodeficiency" near/2 virus*) or ("human immunodeficiency" next virus*) or ("human immuno-deficiency" next virus*))):ti,ab,kw 20 #7 (without next (HIV or "HIV-1" or HIV1 or "HIV-I" or HIVI or "HIV-2" or HIV2 or "HIV-2" or "HIV-II" or HIVII or HTLV* or "LAV-2" or "LAV-II")):ti,ab,kw 71

7 #8 (without next (AIDS or ("acquired immune deficiency" near/2 virus*) or ("acquired next virus*))):ti,ab,kw 46 #9 ((non or "not") next (HIV or "HIV-1" or HIV1 or "HIV-I" or HIVI or "HIV-2" or HIV2 or "HIV-2" or "HIV-II" or HIVII or HTLV* or "LAV-2" or "LAV-II") next positiv*):ti,ab,kw 5 #10 ((non next positiv*) next (HIV or "HIV-1" or HIV1 or "HIV-I" or HIVI or "HIV-2" or HIV2 or "HIV-2" or "HIV-II" or HIVII or HTLV* or "LAV-2" or "LAV-II")):ti,ab,kw 0 #11 ((non or "not") next (AIDS or ("acquired immune deficiency" near/2 virus*) or ("acquired next virus*)) next positiv*):ti,ab,kw 0 #12 ((non next positiv*) next (AIDS or ("acquired immune deficiency" near/2 virus*) or ("acquired next virus*))):ti,ab,kw 0 #13 {or #1-#12} 1407 #14 [mh "HIV Infections"/PC] 2145 #15 (prevent* near/3 (AIDS or ("acquired immune deficiency" near/2 virus*) or ("acquired next virus*))):ti,ab,kw 675 #16 (prevent* near/3 (HIV or "HIV-1" or HIV1 or "HIV-I" or HIVI or "HIV-2" or HIV2 or "HIV-2" or "HIV- II" or HIVII or HTLV* or "LAV-2" or "LAV-II")):ti,ab,kw 1744 #17 (prophyla* near/3 (AIDS or ("acquired immune deficiency" near/2 virus*) or ("acquired next virus*))):ti,ab,kw 43 #18 (prophyla* near/3 (HIV or "HIV-1" or HIV1 or "HIV-I" or HIVI or "HIV-2" or HIV2 or "HIV-2" or "HIV-II" or HIVII or HTLV* or "LAV-2" or "LAV-II")):ti,ab,kw 197 #19 {or #14-#18} 3205 #20 [mh ^"Anti-Retroviral Agents"] 486 #21 [mh ^"Anti-HIV Agents"] 2456 #22 (antiretrovir* or (anti next retrovir*) or antihiv* or (anti next HIV*) or antiaids or (anti next AIDS)):ti,ab,kw 5715 #23 [mh Adenine/AA] 603 #24 tenofovir*:ti,ab,kw 1138 #25 (rilpivirine or edurant or "TMC-278" or TMC278 or "UNII-FI96A8X663"):ti,ab,kw 99 #26 (dapivirine or "TMC-120" or TMC120 or "UNII-TCN4MG2VXS"):ti,ab,kw 11 #27 Truvada:ti,ab,kw 17 #28 ("TDF-FTC" or "FTC-TDF" or "TDF/FTC" or "FTC/TDF"):ti,ab,kw 274 #29 {or #20-#28} 6391 #30 [mh ^"Primary Prevention"] or [mh "Pre-Exposure Prophylaxis"] 958 #31 #29 and #30 27 #32 #13 and (#19 or #31) 451 #33 #19 and # #34 [mh "HIV Infections"] 8933 #35 [mh HIV] 2824 #36 [mh "HIV Seroprevalence"] 43 #37 (AIDS or ("acquired immune deficiency" near/2 virus*) or ("acquired immunodeficiency" near/2 virus*) or ("human immunodeficiency" next virus*) or ("human immuno-deficiency" next virus*)):ti,ab,kw 10047

8 #38 (HIV or "HIV-1" or HIV1 or "HIV-I" or HIVI or "HIV-2" or HIV2 or "HIV-2" or "HIV-II" or HIVII or HTLV* or "LAV-2" or "LAV-II"):ti,ab,kw #39 {or #34-#38} #40 [mh "Pre-Exposure Prophylaxis"] 25 #41 (((pre next expos*) or preexpos*) near/3 prophyla*):ti,ab,kw 182 #42 (((pre next expos*) or preexpos*) near/3 prevent*):ti,ab,kw 10 #43 PrEP:ti,ab,kw 320 #44 {or #40-#43} 406 #45 (#1 or #2 or #39) and # #46 #32 or #33 or # HTA 2 NHS EED - 75

Urinary incontinence (update) and pelvic organ prolapse in women: management

Urinary incontinence (update) and pelvic organ prolapse in women: management National Institute for Health and Care Excellence Draft for consultation Urinary incontinence (update) and pelvic organ prolapse in women: management Economic study selection NICE guideline tbc Supplementary

More information

Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers Scheid D C, Hamm R M, Stevens K W

Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers Scheid D C, Hamm R M, Stevens K W Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers Scheid D C, Hamm R M, Stevens K W Record Status This is a critical abstract of an economic evaluation

More information

APPENDIX 1. Mindfulness, CBT & Pain Search Strategies Final 2014 Apr 4

APPENDIX 1. Mindfulness, CBT & Pain Search Strategies Final 2014 Apr 4 APPENDIX 1 Mindfulness, CBT & Pain Search Strategies Final 2014 Apr 4 Search Name: Mindfulness CBT Pain - Ottawa Pain Clinic Date Run: 04/04/14 14:34:17.372 Description: Final - 2014 Apr 4 ID Search Hits

More information

Appendix A NHS England clinical care pathways: overview of oral health assessment and oral health review

Appendix A NHS England clinical care pathways: overview of oral health assessment and oral health review 59 Appendix A NHS England clinical care pathways: overview of oral health assessment and oral health review NHS ENGLAND CLINICAL CARE PATHWAYS Simplified overview of Oral Health Assessment and Oral Health

More information

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure

More information

Cost-effectiveness of HIV post-exposure prophylaxis in France Herida M, Larsen C, Lot F, Laporte A, Desenclos J C, Hamers F F

Cost-effectiveness of HIV post-exposure prophylaxis in France Herida M, Larsen C, Lot F, Laporte A, Desenclos J C, Hamers F F Cost-effectiveness of HIV post-exposure prophylaxis in France Herida M, Larsen C, Lot F, Laporte A, Desenclos J C, Hamers F F Record Status This is a critical abstract of an economic evaluation that meets

More information

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis Bayoumi A M, Redelmeier D A

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis Bayoumi A M, Redelmeier D A Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis Bayoumi A M, Redelmeier D A Record Status This is a critical abstract of an economic

More information

Economic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G

Economic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G Economic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G Record Status This is a critical abstract of an economic

More information

The cost-effectiveness of expanded testing for primary HIV infection Coco A

The cost-effectiveness of expanded testing for primary HIV infection Coco A The cost-effectiveness of expanded testing for primary HIV infection Coco A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

More information

PrEP for Women: HIV Prevention in Family Planning Settings

PrEP for Women: HIV Prevention in Family Planning Settings National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov

More information

Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients Das A

Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients Das A Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients Das A Record Status This is a critical abstract of an economic evaluation that meets

More information

Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US

Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US PharmacoEconomics (2013) 31:1091 1104 DOI 10.1007/s40273-013-0111-0 CURRENT OPINION Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US Fred J. Hellinger Published

More information

HIV: The Great Debate On Clinical Approach Vs. Cost Considerations

HIV: The Great Debate On Clinical Approach Vs. Cost Considerations M E D I C A ID H E A L T H P L A N S O F AMERICA HIV: The Great Debate On Clinical Approach Vs. Cost Considerations Steve Miller, MD Chief Medical Officer October 2018 HIV IMPACT: 1.1M Americans affected

More information

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017 HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359

More information

An Update on the US HIV Epidemic and Recent Strides in HIV Care

An Update on the US HIV Epidemic and Recent Strides in HIV Care An Update on the US HIV Epidemic and Recent Strides in HIV Care Boca Raton Regional Hospital Grand Rounds 05/24/2016 Kenneth Poon MD ABIM Infectious Diseases Assoc Prog Dir Asst Prof of Clin Biomed Internal

More information

HIV Prevention Strategies HIV Pre-exposure prophylaxis

HIV Prevention Strategies HIV Pre-exposure prophylaxis HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those

More information

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets

More information

Bilag 5. Søgestreng sekundær og primær litteratur

Bilag 5. Søgestreng sekundær og primær litteratur Bilag 5. Søgestreng sekundær og primær litteratur Søgespecialister Conni Skrubbeltrang og Jette Frost Jepsen Det Nationale Sorgcenter Database Udbyder Resultat Dato Medline Ovid 61 26.06.2017 Embase Ovid

More information

Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1 Halpern M T, Read J S, Ganoczy D A, Harris D R

Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1 Halpern M T, Read J S, Ganoczy D A, Harris D R Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1 Halpern M T, Read J S, Ganoczy D A, Harris D R Record Status This is a critical abstract of an economic

More information

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments There are two options for accessing the audio portion of this webinar: (1) Using your

More information

HIV testing as the bridge between awareness and acceptance of PrEP among MSM

HIV testing as the bridge between awareness and acceptance of PrEP among MSM PA_3 #08 HIV testing as the bridge between awareness and acceptance of PrEP among MSM Tsz Ho Kwan, BSc, MIET PhD Candidate in Public Health 1 June 2017 Content Background HIV epidemiology in Hong Kong

More information

Setting The setting was secondary care. The economic study was carried out in the USA.

Setting The setting was secondary care. The economic study was carried out in the USA. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective Delea T E, Sofrygin

More information

European Medicines Agency decision

European Medicines Agency decision EMA/785816/2015 European Medicines Agency decision P/0294/2015 of 3 December 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for

More information

PrEPX frequently asked questions version 1

PrEPX frequently asked questions version 1 1 PrEPX FAQs version 1 This document will be published on the Alfred Health PrEPX webpage and as a printed hand out for potential study participants. What is HIV PrEP? Pre-Exposure Prophylaxis (PrEP) is

More information

Recurrent Urinary Tract Infections Among Adult Women: Comparative Effectiveness of Five Prevention. Chain Monte Carlo Model

Recurrent Urinary Tract Infections Among Adult Women: Comparative Effectiveness of Five Prevention. Chain Monte Carlo Model Recurrent Urinary Tract Infections Among Adult Women: Comparative Effectiveness of Five Prevention and Management Strategies Using A Markov Chain Monte Carlo Model Samantha J. Eells, M.P.H. 1, Kirin Bharadwa,

More information

Guidelines for PrEP in PWID

Guidelines for PrEP in PWID Guidelines for PrEP in PWID Any use of injection drugs (past 6 months) AND Any sharing of injection equipment OR participation in methadone, naloxone, or buprenorphine treatment program (past 6 months)

More information

BLT mice in HIV prophylaxis

BLT mice in HIV prophylaxis BLT mice in HIV prophylaxis Martina Kovarova, Ph.D. Assistant Professor UNC at Chapel Hill September 18, 2017 BLT mice Bone Marrow-Liver-Thymus Melkus, et al., Nature (2006) BLT humanized mice preparation

More information

Appendix 1. Search strategies for individual databases

Appendix 1. Search strategies for individual databases Appendix 1. Search strategies for individual databases OVID Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)

More information

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search Search 1 :When to Initiate ART Covers Questions 1-5 including to prevent transmission Component Description Review area Objectives

More information

1. Comparative effectiveness of liraglutide

1. Comparative effectiveness of liraglutide Cost-effectiveness of liraglutide (Victoza ) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding

More information

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global

More information

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners November 2017 Rationale for resource This resource is designed to support registered practitioners involved in

More information

tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd

tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd 05 August 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil

More information

Source of effectiveness data The effectiveness evidence was derived from a single study that was identified from a review of the literature.

Source of effectiveness data The effectiveness evidence was derived from a single study that was identified from a review of the literature. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK Guest J F, Clegg J P, Davie A M, McCloskey E Record Status This is a critical

More information

Guideline topic: Sore Throat Review

Guideline topic: Sore Throat Review Guideline topic: Sore Throat Review General comments Search coverage Patient searches Medline, Embase, CINAHL, PsycInfo Guidelines (run on) The guideline search used the patient stem. Guidelines evaluated

More information

Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis Little S E, Caughey A B

Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis Little S E, Caughey A B Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis Little S E, Caughey A B Record Status This is a critical abstract of an economic evaluation

More information

PrEP: Pre Exposure Prophylaxis

PrEP: Pre Exposure Prophylaxis PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose

More information

CCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period

CCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period CCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period There are currently no published guidelines for post-exposure prophylaxis from the CDC/PHS specific to the pediatric population. This

More information

Cost-effectiveness analysis of screening for celiac disease in the adult population Shamir R, Hernell O, Leshno M

Cost-effectiveness analysis of screening for celiac disease in the adult population Shamir R, Hernell O, Leshno M Cost-effectiveness analysis of screening for celiac disease in the adult population Shamir R, Hernell O, Leshno M Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Multiple choice questions: ANSWERS

Multiple choice questions: ANSWERS Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible

More information

The cost-utility of screening for depression in primary care Valenstein M, Vijan S, Zeber J E, Boehm K, Buttar A

The cost-utility of screening for depression in primary care Valenstein M, Vijan S, Zeber J E, Boehm K, Buttar A The cost-utility of screening for depression in primary care Valenstein M, Vijan S, Zeber J E, Boehm K, Buttar A Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

19 th May The clinical and cost effectiveness of laparoscopic surgery for colorectal cancer. Aberdeen Technology Assessment Review Group

19 th May The clinical and cost effectiveness of laparoscopic surgery for colorectal cancer. Aberdeen Technology Assessment Review Group Technology Assessment Report Commissioned by the NHS R&D HTA Programme on behalf of the National Institute for Health and Clinical Excellence Final Protocol 1. Title of the project: 19 th May 2005 The

More information

Pre-exposure prophylaxis (PrEP) in. in HIV-uninfected individuals with high-risk. behaviour

Pre-exposure prophylaxis (PrEP) in. in HIV-uninfected individuals with high-risk. behaviour Review Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour S. Nadery, S.E. Geerlings* Department of Internal Medicine, Infectious Diseases Division, Academic Medical

More information

APPENDIX 1: FORMULARY STATUS 1 OF rhgh PRODUCTS IN CANADA BY PROVINCE AND PRODUCT

APPENDIX 1: FORMULARY STATUS 1 OF rhgh PRODUCTS IN CANADA BY PROVINCE AND PRODUCT APPENDIX 1: FORMULARY STATUS 1 OF rhgh PRODUCTS IN CANADA BY PROVINCE AND PRODUCT SK 2 NS 3 NB BC MB AB 13 NL 14 ON 15 FNIHB 16 PEI 17 YT 18 rhgh product DIN Humatrope 745626 R R B 4,R 5 B 6,R 7 B 8, L

More information

Genital Trauma *************************** Ureteral Trauma

Genital Trauma *************************** Ureteral Trauma Genital Trauma September 26>, Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily 1 exp genital injury/ (4099) 2 (penis/ or testis/ or vagina/) and (blunt trauma/ or penetrating

More information

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids Beinfeld M T, Bosch J L, Isaacson K B, Gazelle G S Record Status This is a critical abstract of an economic evaluation

More information

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary

Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease Summary Mai 17 th 2017 Background Alzheimer s disease is a serious neurocognitive disorder which is characterized

More information

Appendix 3 Search strategies

Appendix 3 Search strategies Appendix 3 Search strategies Literature search The evidence reviews used to develop the guideline recommendations were underpinned by systematic literature searches, following the methods described in

More information

What's new in the WHO ART guidelines How did markets react?

What's new in the WHO ART guidelines How did markets react? WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting

More information

HIV. The Role of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV. Brief History of HIV AIDS. Global HIV Infection.

HIV. The Role of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV. Brief History of HIV AIDS. Global HIV Infection. The Role of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV HIV Sarah Kemink, PharmD, AAHIVP WMSHP Spring Seminar 5/05/2015 AIDS CD4 less than 200 +/- AIDS-defining illness Most common: Candidiasis

More information

Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials. Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA

Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials. Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA Mucosal Assays in Oral and Long Acting (LA) Antiretroviral PrEP Trials Ian McGowan MD PhD FRCP University of Pittsburgh Pittsburgh, PA USA Overview A brief history of oral/la PrEP research Integration

More information

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987

More information

Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers

Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP

More information

Source of effectiveness data The effectiveness evidence was derived from a systematic review of published studies.

Source of effectiveness data The effectiveness evidence was derived from a systematic review of published studies. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States Gupta A K Record Status This is a critical

More information

Setting The setting was secondary care. The economic study was conducted in Australia.

Setting The setting was secondary care. The economic study was conducted in Australia. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation Tilden D P, Chapman J, Davey P J, Solly M L, Crowley

More information

Drug development in relation to PrEP and the PROUD study

Drug development in relation to PrEP and the PROUD study Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals

More information

DEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA

DEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA DEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA 22042-5101 DHA-IPM 18-020 MEMORANDUM FOR ASSISTANT SECRETARY OF THE ARMY (MANPOWER AND RESERVE AFFAIRS) ASSISTANT SECRETARY

More information

Four search strategies used- COPD, bronchiectasis, restrictive lung disease, and asthma.

Four search strategies used- COPD, bronchiectasis, restrictive lung disease, and asthma. b) Web appendix: Literature Search details Sources to be searched for the guidelines; Reviews (CDSR) Database of Abstracts of Reviews of Effects (DARE) Dates searched: 1980 onwards All study types English

More information

Economic evaluation of health promotion activities for older people conceptual questions

Economic evaluation of health promotion activities for older people conceptual questions Economic evaluation of health promotion activities for older people conceptual questions Pro Health 65+ Health promotion and prevention of risk Action for Seniors EUHEA Conference 2016, Hamburg Know the

More information

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples

More information

2019 EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Search Strategies

2019 EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Search Strategies 2019 EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Search Strategies General scope search Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily

More information

Should an additional dose of measles-containing vaccine be recommended for HIVinfected adolescents and adults?

Should an additional dose of measles-containing vaccine be recommended for HIVinfected adolescents and adults? Should an additional dose of measles-containing vaccine be recommended for HIVinfected adolescents and adults? Introduction At the October 2015 meeting of the Strategic Advisory Group of Experts (SAGE)

More information

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000. Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD

More information

entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd

entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has

More information

Study population The study population comprised HIV-infected pregnant women seeking antenatal care.

Study population The study population comprised HIV-infected pregnant women seeking antenatal care. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries Sweat M D, O'Reilly K R, Schmid G P, Denison J, de Zoysa I Record Status This is a critical abstract

More information

Health and economic consequences of HCV lookback Pereira A

Health and economic consequences of HCV lookback Pereira A Health and economic consequences of HCV lookback Pereira A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a

More information

New antiretroviral agents efficacy and safety. Rilpivirine Elvitegravir Both agents with Truvada,+/- cobicistat (not in search terms)

New antiretroviral agents efficacy and safety. Rilpivirine Elvitegravir Both agents with Truvada,+/- cobicistat (not in search terms) Appendix 4 BHIVA Treatment Guideline update 20 Search protocol: main databases search: rilpivirine and elvitegravir Component Review area Objectives Populations Description New antiretroviral agents efficacy

More information

CONTENTS. New Zealand s personal importation scheme for medicines. What is PrEP? Who will benefit from PrEP? Sex between men

CONTENTS. New Zealand s personal importation scheme for medicines. What is PrEP? Who will benefit from PrEP? Sex between men CONTENTS 4 What is PrEP? 6 Who will benefit from PrEP? Sex between men 7 Sex between men and women 8 What happens when I start on PrEP? 9 What if I want to stop using PrEP? Where can I get PrEP in New

More information

Primer on Simulation Modeling: Using Model-Based Analyses to Inform Health Policy and Research on HIV Prevention

Primer on Simulation Modeling: Using Model-Based Analyses to Inform Health Policy and Research on HIV Prevention Primer on Simulation Modeling: Using Model-Based Analyses to Inform Health Policy and Research on HIV Prevention Caitlin Dugdale, MD Massachusetts General Hospital Global HIV Vaccine Enterprise Modeling

More information

A cost-utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients Stylopoulos N, Gazelle G S, Rattner D W

A cost-utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients Stylopoulos N, Gazelle G S, Rattner D W A cost-utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients Stylopoulos N, Gazelle G S, Rattner D W Record Status This is a critical abstract of an economic evaluation

More information

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,

More information

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Scottish Health Protection Network HIV Clinical Leads FINAL Approved for circulation 17 May 2017 Version No. 6.2 (04/05/17) Date

More information

The Hospital for Sick Children Technology Assessment at SickKids (TASK) FULL REPORT

The Hospital for Sick Children Technology Assessment at SickKids (TASK) FULL REPORT The Hospital for Sick Children Technology Assessment at SickKids (TASK) FULL REPORT WILL THE GROWTH SPURT CONTINUE? TRENDS IN CHILD HEALTH ECONOMIC EVALUATION: 1980 TO 2013 Authors: Shannon Sullivan, PhD

More information

2018 EAU Non-muscle-invasive Bladder Cancer Guidelines Search Strategies

2018 EAU Non-muscle-invasive Bladder Cancer Guidelines Search Strategies 2018 EAU Non-muscle-invasive Bladder Cancer Guidelines Search Strategies Database: Embase , OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)

More information

Risk Management Plan Summary

Risk Management Plan Summary Risk Management Plan Summary EDURANT (rilpivirine) 25 mg film-coated tablet Document Version: 1.0 Document Date: 30.10.2017 Based on EU RMP version 7.0 Marketing authorization holder: Janssen-Cilag AG,

More information

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018 The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and

More information

Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation

Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February 2016 - NHS England Evidence Review: Comparison of tenofovir alafenamide and tenofovir disoproxil fumarate.

More information

Basic Economic Analysis. David Epstein, Centre for Health Economics, York

Basic Economic Analysis. David Epstein, Centre for Health Economics, York Basic Economic Analysis David Epstein, Centre for Health Economics, York Contents Introduction Resource use and costs Health Benefits Economic analysis Conclusions Introduction What is economics? Choices

More information

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants. Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

Using anti-hiv drugs for prevention

Using anti-hiv drugs for prevention Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment

More information

Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T

Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation

More information

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure

More information

Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak. Pilkington et al. Glasgow HIV Poster 0143

Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak. Pilkington et al. Glasgow HIV Poster 0143 Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak 36.7 Million 1.8 Million 1 Million NEW INFECTIONS LIVING WITH HIV DEATHS https://www.avert.org/global-hiv-and-aids-statistics.

More information

Pharmaceutical reimbursement in Sweden Balancing benefits and costs. Andreas Engström Health Economist Dental and Pharmaceutical Benefits Agency

Pharmaceutical reimbursement in Sweden Balancing benefits and costs. Andreas Engström Health Economist Dental and Pharmaceutical Benefits Agency Pharmaceutical reimbursement in Sweden Balancing benefits and costs Andreas Engström Health Economist Dental and Pharmaceutical Benefits Agency 1 Agenda Background - Healthcare in Sweden - Pharmaceutical

More information

Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know

Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know ANTONIO E. URBINA, MD Medical Director Associate Professor of Medicine Mt. Sinai Hospital Disclosure

More information

A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis Das A

A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis Das A A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis Das A Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Genvoya Gilead Sciences Canada, Inc.) Indication: HIV-1 Infection Recommendation:

More information

Moving PrEP Forward. Where We Are & Where We Need to Go. Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases

Moving PrEP Forward. Where We Are & Where We Need to Go. Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases Moving PrEP Forward Where We Are & Where We Need to Go Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases Overview Recent study results & some context o o o Epidemiology

More information

Clinical and Public Health Policy Implications of Findings that:

Clinical and Public Health Policy Implications of Findings that: Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome

More information

WHO s early release guidelines on PrEP: implications for emtct. Dominika Seidman, MD October 13, 2015

WHO s early release guidelines on PrEP: implications for emtct. Dominika Seidman, MD October 13, 2015 WHO s early release guidelines on PrEP: implications for emtct Dominika Seidman, MD October 13, 2015 Outline Evidence behind WHO early release guidelines on PrEP PrEP eligibility according to the WHO Rationale

More information

Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets 30.5.2016, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary Emtricitabine / Tenofovir

More information

Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination

Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination Harlan Pruden Educator, Chee Mamuk, Aboriginal Program BC Center for Disease Control, Clinical Prevention Services Sḵwx on the traditional, ancestral

More information

Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J

Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J Record Status This is a critical abstract of an economic evaluation

More information

How to order generic PrEP online Find a doctor who prescribes PrEP Learn how to prescribe PrEP Information for doctors. What is PrEP?

How to order generic PrEP online Find a doctor who prescribes PrEP Learn how to prescribe PrEP Information for doctors. What is PrEP? 4 What is PrEP? 6 Who will benefit from PrEP? 7 Men (cis or trans) and trans women who have sex with men Partners of people living with HIV 8 Take the quiz: Is PrEP right for me? What are the options for

More information

EU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3

EU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3 VI.2 Elements for a public summary 200 mg/245 mg film-coated tablets VI.2.1 Overview of disease epidemiology HIV-1 infection In this decade, the global prevalence of HIV-1 infection stabilized

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment

More information